Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2023 Earnings Call Transcript
Corvus Pharmaceuticals, Inc. reports earnings inline with expectations. Reported EPS is $-0.14 EPS, expectations were $-0.14.
Corvus Pharmaceuticals Inc. (CRVS)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | OrbiMed Advisors Samuel Isaly | 6,943,654 | $12,220,831 | 0.24% | |
| 2. | Adams Street Partners Jeffrey Diehl | 3,275,616 | $5,765,084 | 1.77% | |
| 3. | Samlyn Capital Robert Pohly | 2,496,259 | $4,393,416 | +4% | 0.08% |
| 4. | Biotechnology Value Fund / BVF Inc Mark Lampert | 1,370,947 | $2,412,867 | 0.06% | |
| 5. | Two Sigma Advisors John Overdeck And David Siegel | 235,600 | $414,656 | -6% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.45 | 10,000 | 10,000 | 2023-05-15 | Filing | ||
| $0.79 | 20,000 | Officer | 133,773 | 2022-12-20 | Filing | |
| $0.84 | 4,000 | Officer | 133,238 | 2022-12-14 | Filing | |
| $0.74 | 30,000 | Officer | 129,238 | 2022-12-13 | Filing | |
| $0.78 | 10,000 | Officer, Director | 1,490,119 | 2022-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.96 | 2,000,000 | Large Shareholder | 81,077 | 2021-10-01 | Filing | |
| $5.04 | 3,000,000 | Large Shareholder | 2,081,077 | 2021-09-30 | Filing | |
| $6.09 | 1,109,644 | Large Shareholder, Director | 6,943,654 | 2021-09-20 | Filing | |
| $6.09 | 1,109,644 | Large Shareholder, Director | 6,943,654 | 2021-09-20 | Filing | |
| $5.37 | 741,440 | Large Shareholder | 1,389,498 | 2020-07-08 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 1,350,633 | $2,377,114 | 0% | |
| 2. | 520,551 | $916,170 | 0% | |
| 3. | 436,873 | $768,896 | 0.46% | |
| 4. | 360,380 | $634,410 | 0% | |
| 5. | 259,655 | $456,992 | 0% |
News See All
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q3 2023 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen. Thank you for standing by, and welcome to the Corvus Pharmaceuticals Third Quarter 2023 Business Update and Financial Results Conference Call.
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q2 2023 Earnings Call Transcript
Operator: Thank you for standing by. This is the conference operator. Welcome to the Corvus Pharmaceuticals Second Quarter 2023 Conference Call. [Operator Instructions].
Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Q4 2022 Earnings Call Transcript
Operator: Good afternoon, ladies and gentlemen.
10 Best Stocks to Buy Now According to Jeffrey Diehl's Adams Street Partners
In this article, we will be taking a look at some of the top stocks in the portfolio of Jeffrey Diehl.
Top 10 Stock Picks of Jeffrey Diehl's Adams Street Partners
In this article, we will be taking a look at the top 10 stock picks of Jeffrey Diehl's Adams Street Partners.
Why These 5 Stocks Are On the Move on Friday
5. United States Steel Corporation (NYSE:X) is around 8% lower today after the company provided a third quarter update.
Hedge Fund and Insider Trading News: Warren Buffett, Bill Ackman, Ken Griffin, Crispin Odey, Anthony Scaramucci, Corvus Pharmaceuticals Inc (CRVS), Carnival Corp (CCL), and More
A historic economic comeback is sending some of the world’s biggest investors bargain hunting in the unloved energy sector.
Should You Buy Corvus Pharmaceuticals, Inc. (CRVS)?
Insider Monkey has processed numerous 13F filings of hedge funds and successful value investors to create an extensive database of hedge fund holdings.
Billionaire Hedge Funds
